CT Body Composition Enhances Survival Risk Stratification

NCT07109271 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 227

Last updated 2025-08-11

No results posted yet for this study

Summary

Gastric carcinoma remains the fifth most common malignancy and the second leading cause of cancer-related mortality worldwide. For patients with locally advanced disease, standard treatment includes radical gastrectomy followed by (neo)adjuvant chemotherapy and immune checkpoint inhibitors. Considerable variability in prognosis persists even within the same the American Joint Committee on Cancer (AJCC) substage, highlighting the importance of host-related factors such as nutritional status, systemic inflammation, and immune competence in shaping survival.

Computed tomography-based body composition (CTBC) analysis offers an objective means to quantify skeletal muscle, subcutaneous adipose tissue, and visceral adipose tissue, capturing key dimensions of patient physiology that are not accounted for in traditional staging systems. Advances in deep learning enables rapid, automated body composition analysis with high concordance to expert annotations.

Here, the investigators prepare to apply automated CTBC analysis to a homogeneous cohort of 300 patients with AJCC8 stage III gastric cancer to determine whether visceral adiposity-related metrics improve survival risk stratification beyond TNM staging.

Conditions

Sponsors & Collaborators

  • Ministry of Health and Welfare, Taiwan

    collaborator OTHER_GOV
  • Chang Gung Memorial Hospital

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-01
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07109271 on ClinicalTrials.gov